麻将胡了2
Skip to content
Home
Management Team
Pipeline
Collaboration
News
Contact Us
中文
Toggle Menu
InventisBio Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients with Moderate to Severe Plaque Psoriasis
12/03/2024
Officially Approved. Anfangning (KRAS G12C Inhibitor Garsorasib) Receives Market Authorization from the National Medical Products Administration (NMPA) of China
11/11/2024
2024 WCLC | Latest Progress of Garsorasib (D-1553) in Treating KRAS G12C-Mutant Lung Cancer: Phase 2 Study Updates
09/10/2024
Garsorasib (D-1553) New Indication Added to Breakthrough Therapy Designation Program
06/13/2024
Garsorasib (D-1553) Phase II Study Results for Lung Cancer Published in Prestigious International Journal
06/11/2024
InventisBio to Present Phase II Clinical Data of Garsorasib (D-1553) for Lung Cancer at the 2024 AACR Annual Meeting
03/13/2024
? InventisBio Co., Ltd? ? ? ? ? ? 沪ICP备2021024579号-1 ?????沪公网安备31011502020033
Home
Management Team
Pipeline
Collaboration
News
Contact Us
中文
【网站地图】
